quarter fiscal Q available our that provide year. the filings. our the always filed you, for nine December Thank our everyone on is as today. of XX, of elitepharma.com, website, Investor quarter and the year, The section as is other websites the is XXXX. XX-Q on a months which December the our well Yesterday, the ended third so We're Nasrat. quarter in calling fiscal and for March And thanks XXXX as sec.gov links we to
the the analysis, Q of like of and some gotten financials, please to If any I'd of the numbers. into from the context key through you Today, or parts providing the insight a sites. haven't yet, get copy other elitepharma.com review
those do to and Elite shareholders questions and related financials. followers, from address and are my I'll As that the to always, we've received best questions comments
XXXX reported year-on-year Revenues revenue row or digit quarter in for on So a ended have December another with in where that $X.XX makes we quarters XXXX basis. now, growth double quarter, on compared triple where of to million as year. The let's launched growth to increase million digit a $X seven extended the were revenues $X.XX was XX% XXth from double we increase the compared last P&L, start was achieved revenues the that’s or so which Adderall, quarter March release year. same this the December with driven by generic million as
immediate strong saw and also generic compared We as capsules. last release Dantrolene generic to for year growth Adderall
continuing Our revenues. products with Phendimetrazine and also consistent other Naltrexone Phentermine, solid continued to Isradipine, their contributions performance,
and now. provide excellent products indicate Adderall job Naltrexone We the certain and generic products expanding the additional nine year products. stable generic these share. alliance revenues And in immediate retrospectively product do the prospectively, revenue Adderall, launched the that penetrating only product or evidenced we our little ago, growth continue launched by Remember, less continue new should future a seeming factors an just ago. to to out driver, market, partner stand It's release they they for as While Isradipine a relatively year release a than And as Phendimetrazine both reported with many still and for Phentermine, do our products the years they've are upside these done to as Lannett, continue with market. over so. and months the a extended market
prospectively. positive takeaway factors the have on here evidenced calls, remain seven year-on-year these that growth they and P&L their the past driven that are previous our So continue contributions mentioned clearly factors were quarters results should the substantial the and in over is The statements.
Elite. basis and profits quarter, the of fiscal quarter third to and since significant profits XX% On XXXX, was the the in Moving we nine an December down operating And profit to year-to-date X.X profitability, this million achieved operating has consecutive an XXXX the that's million, of that's year. to to with statement, profit – to $XXX,XXX four That's first That's million an of $X month for of quarter. turnaround improvement compared P&L operating a a the December, a during led a in operating same $XXX,XXX the profit last loss from strengthening our to months operating nine $X.X compared financials. for period April our in XXXX. that's
a from more operations goes more that's year. working Our a balance that $X.X an have to capital operating cash And And improvement $XXX,XXX our nine generated flow. sheet of during million of to $X.X compared That's stronger obviously burn year. this a has months. with than last sheet quadrupled than it. $X.X million balance $X.X cash And, last the positive million million flow in
cash that's revenues sheet. positive flows increased balance and and the So the the strengthening impact a profits, of
asking last over that's good for And Thanks And Now, turning and NASDAQ That's our And a get is, and is question a received, is a question. answer are which things lot. I you the much I as one to before that uplisting might still okay Nasrat question the planning very a status? thing still Nasrat. now. uplisting? yes, with it. well That's what in on plans.
and profits, and to And important, as attention past, great be the the on means in And to those shaping to cash been factors. is As are that nicely. over and financial order up continue there's others and level Oftentimes, XX products, center cases, further you product But triple-digit controlling us past hand, products, so in we've a debt, fundamentals there notable debt, growing so improvement NASDAQ, fundamentals financials revenues can substantial to And growth, our products, us continually given fundamentals from but recently. rates products. in uplift on which just commercializing our the on, see double debt under. we many incurring XX from there's as a Elite's I incurring without flows, at going of my of drag focus level more requires we've have standpoint the this been and have the months. developing this other which as of side, companies on industry. the new the these said, and is examples a increasing detriment front financials, of develop means in for to from anywhere that near acts to financial most incurred been in require positive the results to financial been few other by revenues, future developing Elite development, some Elite's commercialize the to are
this at through fiscal financed that. no financing, debt. been has first, growth from debt. cash repeat and year flows most internal for Our of I alone, equity No
three we to are in relatively how generic I market. our some just peers free in that when talk three in there being ratios focus debt of debt-related place, comparison is So about we And fundamentals all on. the demonstrate
the long-term is ratio cap. of First to current market debt
X% market cap. than XXX%, which to of Amneal Now Elite’s debt long-term is That XXX%, and Endo, Teva, XXX%. is our compares which less is
four and of these have XX more are market two, So the and long-term our is three times they and caps market their that loans it's times opposite. larger, just It's our Elite than loans. that each companies, cap that's
our focus on a lot the ratio, equity. debt Second is long-term ratio between and
billion XXX% is with is negative And and which has So that Elite’s compares Teva, debt approximately of than its Endo, equity in and which $X Amneal more XX% XXX%, equity. debt. long-term long-term
others debts its equity, a are of their while of multiples Elite’s that equity. So debt have fraction is
expense. interest ratio and Interest third -- interest EBIT earned and Earnings Taxes that The Before relation measures that ratio the is to really in times sticks out
ratio So indicates than higher expense. this due underlying number is a revenues debt to interest where being financials the stronger and greater
So one Amneal, and Elite’s and times for one that’s for interest three compared Endo. is to XX ratio for Teva
development earnings, product level available low development. our to thanks companies, consume debt, their portions of that compared large and as percentage expense less which greater much means debt for this product have for available have of of interest So other a leaving to we that earnings
So of fund to cash – we're year why internally the reasons one flows. development product from this internal able
the is balance critical on say uplisting if uplisting, status you achieving from the standpoint cash statement, they've our everything doing fundamentals flow sheet and to and the need about an on among is do together. in in see path actually and ask to the would improved need the sector. this. P&L of to financial statement meeting we in The that a substantially, strongest This some and well So the me cases we're are coming the I
things ratios and the our cash to positive, continue financials revenues coming is are to low, strengthen, are very from sum flow up, on perspective, and up -- fundamentals a target. finance debt So together is low
as You going know, things being this don't track. nice always go much as planned on and planned, see so to but is it's
his like give and to Nasrat and update an Now our comments. Hakim, CEO, Chairman Mr.
